Answers are grounded in this paper and cite their sources.
Bevacizumab with chemoradiotherapy appears safe and active and yields promising survival results in locally advanced rectal cancer. Plasma VEGF, PlGF, sVEGFR1, and IL-6 and CECs should be further evaluated as candidate biomarkers of response for this regimen.
No takes yet. Share an insight, caveat, or question.
Willett et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: